** Shares of the New York-based drug developer IN8bio INAB.O rises 17.5% to 31 cents

** Co says early-stage trial showed its experimental cancer therapy helped all 9 patients with a type of blood cancer remain in complete remission

** Co's therapy, INB-100, also helped increase survival rates of patients compared to historical data and the time they lived without their cancer worsening

** INAB was testing its therapy to treat acute myeloid leukemia, a cancer of the blood and bone marrow

** INB-100 uses gamma-delta T cells, that are rarely found in secondary lymphoid organs and play a role in helping control cancer activity, to target the disease

** Patients treated with INB-100 also showed prolonged and durable decrease in symptoms of their cancer beyond one year

** In the last 12 months, INAB has fallen 70.27%

(Reporting by Siddhi Mahatole)

((siddhiprabhanjan.mahatole@thomsonreuters.com))